SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies…
Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital setting.Ongoing…